VYNE Therapeutics (VYNE) Stock Forecast & Price Target

$2.09

-0.01 (-0.48%)

(As of 07/26/2024 ET)

VYNE Therapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy
Based on 1 Analyst Ratings

Based on 1 Wall Street analysts who have issued ratings for VYNE Therapeutics in the last 12 months, the stock has a consensus rating of "Buy." Out of the 1 analysts, 1 has given a buy rating for VYNE.

Consensus Price Target

$5.75
175.12% Upside

High Forecast	$5.75
Average Forecast	$5.75
Low Forecast	$5.75

According to the 1 analysts' twelve-month price targets for VYNE Therapeutics, the average price target is $5.75. The highest price target for VYNE is $5.75, while the lowest price target for VYNE is $5.75. The average price target represents a forecasted upside of 175.12% from the current price of $2.09.

Type	Current Forecast 7/28/23 to 7/27/24	1 Month Ago 6/28/23 to 6/27/24	3 Months Ago 4/29/23 to 4/28/24	1 Year Ago 7/28/22 to 7/28/23
Consensus Rating	Buy	Buy	Buy	Moderate Buy
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	1 Buy rating(s)	1 Buy rating(s)	1 Buy rating(s)	1 Buy rating(s)
Hold	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)	1 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$5.75	$5.75	$7.38	$18.50
Forecasted Upside	175.12% Upside	161.36% Upside	111.93% Upside	269.51% Upside

Get VYNE Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for VYNE and its competitors with MarketBeat's FREE daily newsletter.

Ad Behind the Markets

J.P. Morgan’s DIRE Warning

When the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal warns, "America's bonds are getting harder to sell."

Click here to see why Wall Street is in PANIC mode >>>

VYNE Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

VYNE Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

VYNE Therapeutics Stock vs. The Competition

Type	VYNE Therapeutics	Medical Companies	S&P 500
Consensus Rating Score	3.00	2.72	2.50
Consensus Rating	Buy	Moderate Buy	Moderate Buy
Predicted Upside	175.12% Upside	3,123.40% Upside	9.10% Upside
News Sentiment Rating	Positive News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
6/14/2024	HC Wainwright 3 of 5 stars		Reiterated Rating	Buy ➝ Buy	$5.75 ➝ $5.75	+161.36%
5/12/2023	Cantor Fitzgerald 3 of 5 stars		Boost Target		$5.00 ➝ $9.00	+47.54%
8/12/2022	Lifesci Capital 2 of 5 stars	P. Dolezal Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 01:40 AM ET.

VYNE Forecast - Frequently Asked Questions

What is VYNE Therapeutics' forecast for 2024?: According to the research reports of 1 Wall Street equities research analysts, the average twelve-month stock price forecast for VYNE Therapeutics is $5.75, with a high forecast of $5.75 and a low forecast of $5.75.
Should I buy or sell VYNE Therapeutics stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for VYNE Therapeutics in the last twelve months. There is currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" VYNE shares.
Does VYNE Therapeutics's stock price have much upside?: According to analysts, VYNE Therapeutics's stock has a predicted upside of 161.36% based on their 12-month stock forecasts.
What analysts cover VYNE Therapeutics?: VYNE Therapeutics has been rated by research analysts at HC Wainwright in the past 90 days.
Do Wall Street analysts like VYNE Therapeutics more than its competitors?: Analysts like VYNE Therapeutics more than other "medical" companies. The consensus rating for VYNE Therapeutics is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how VYNE compares to other companies.